Ranitidine and omeprazole effect on serum phosphorus in hemodidlysis patients

Simple item page
dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorElbohy D.
dc.contributor.authorEl-Hamamsy M.
dc.contributor.authorEl-Sharkawy M.
dc.contributor.otherClinical pharmacy
dc.contributor.otherFaculty of pharmacy
dc.contributor.otherMSA University
dc.contributor.otherEgypt; Clinical Pharmacy Department
dc.contributor.otherFaculty of pharmacy
dc.contributor.otherAin Shams University
dc.contributor.otherEgypt; Internal Medicine and Nephrology
dc.contributor.otherFaculty of Medicine
dc.contributor.otherAin Shams University
dc.contributor.otherEgypt
dc.date.accessioned2020-01-25T19:58:29Z
dc.date.available2020-01-25T19:58:29Z
dc.date.issued2011
dc.descriptionScopus
dc.description.abstractHyperphosphatemia induces extraskeletal calcification of soft tissue, a link found between gastric hyperacidity and hyperphosphatemia in dialysis patients. Patientsts categorized into 3 groups viz., Group I (38 Patients) control group, Group II (39 Patients) CaCo 3 with Ranitidine 150 mg and Group III (31 subjects) same dose calcium carbonate with Omeprazole 20 mg. Blood samples were collected monthly during hemodialysis sessions.Group II showed increase in serum phosphorus at 6 th months with increase in calcium-phosphorus biproduct, decreased serum calcium. Group III showed no significant change in serum calcium, phosphorus, Parathyroid hormone and calcium-phosphorus biproduct value. Co-administration of Ranitidine with calcium carbonate may aggravate hyperphosphatemia increasing the incidence of complications. Co-administration of Omeprazole with calcium carbonate may have a beneficial role in minimizing those complications in those patients.en_US
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=20600195619&tip=sid&clean=0
dc.identifier.doihttps://doi.org/
dc.identifier.issn9756299
dc.identifier.otherhttps://doi.org/
dc.identifier.urihttps://t.ly/bLgR7
dc.language.isoEnglishen_US
dc.relation.ispartofseriesInternational Journal of Pharma and Bio Sciences
dc.relation.ispartofseries2
dc.subjectHyperphosphatemiaen_US
dc.subjectHypocalcemiaen_US
dc.subjectOmeprazoleen_US
dc.subjectRanitidineen_US
dc.subjectcalciumen_US
dc.subjectcalcium carbonateen_US
dc.subjectcalcium phosphateen_US
dc.subjectomeprazoleen_US
dc.subjectparathyroid hormoneen_US
dc.subjectphosphateen_US
dc.subjectranitidineen_US
dc.subjectadulten_US
dc.subjectarticleen_US
dc.subjectblood analysisen_US
dc.subjectcalcium blood levelen_US
dc.subjectchronic kidney failureen_US
dc.subjectclinical effectivenessen_US
dc.subjectcontrolled clinical trialen_US
dc.subjectcontrolled studyen_US
dc.subjectdisease exacerbationen_US
dc.subjectdrug effecten_US
dc.subjectdrug efficacyen_US
dc.subjectfemaleen_US
dc.subjectgastric hyperacidityen_US
dc.subjecthemodialysisen_US
dc.subjecthumanen_US
dc.subjecthyperphosphatemiaen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectparathyroid hormone blood levelen_US
dc.subjectphosphate blood levelen_US
dc.subjecttreatment durationen_US
dc.titleRanitidine and omeprazole effect on serum phosphorus in hemodidlysis patientsen_US
dc.typeArticleen_US
dcterms.isReferencedByBlock, G.A., Klassen, P.S., Lazarus, J.M., Ofsthun, N., Lowrie, E.G., Chertow, G.M., Mineral metabolism, mortality and morbidity in maintenance hemodialysis (2004) J Am SocNephrol, 15, pp. 2208-2218; Ganesh, S.K., Stack, A.G., Levin, N.W., Hulbert-Shearon, T., Port, F.K., Association of elevated serum P, Ca x P product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients (2001) J Am SocNephrol, 12, pp. 2131-2138; Block, G.A., Port, F.K., Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management (2000) Am J Kidney, 596, pp. 1226-1237; Jono, S., McKee, M.D., Murry, C.E., Shioi, A., Nishizawa, Y., Mori, K., Phosphate regulation of vascular smooth muscle cell calcification (2000) Circ Res, 87, pp. 10-17; Stern, J., Lewis, W.H.P., The colorimetric estimation of calcium in serum with ocresolphthalein complexone (1957) Clin Chem Acta, 2 (6), pp. 576-580; Sarkar, B.C.R., Chauhan, U.P.S., A new method of determining micro quantities of calcium in biological materials (1967) Anal Biochem, 20, pp. 155-166; Fiske, C.H., Subbarow, Y., The colorimetric determination of phosphorus (1925) Biol Chem, 66, pp. 375-400; Goodwin, J.F., Quantification of Serum Inorganic Phosphorus (1970) Clin Chem, 16 (9), pp. 776-780; Fujita, H., Uber die microbestimmung der Bult phosphatase (1939) Biochem, 30, p. 69; Bowers, G.N., Mccombr, B., A continuous spectrophotometric method for measuring the activity of serum Alk.phos (1966) Clin Chem, 12, pp. 70-89; Armitage, E.K., Parthyrin metabolism and methods for assay (1986) Clin Chem, 3232, pp. 418-424; Kao, P.C., Grant, C.S., Klee, G.G., Khosla, S., Clinical performance of parathyroid hormone immunometric assays (1992) Mayo Clin Proc, 67, pp. 637-645; Slatopolsky, E., Weerts, C., Lopez-Hilker, S., Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis (2005) N Engl J Med, 3 (15), pp. 157-161; Definition and classification of stages of chronic kidney disease (2003) Am J Kidney Dis, 42, pp. 46-75. , National Kidney Foundation: K/DOQI; Tan, C.C., Harden, P.N., Rodger, R., Rowe, P.A., Spooner, R.J., Junor, J.R., Ranitidine reduces phosphate binding in dialysis patients receiving calcium carbonate (1996) Nephrol Dial Transplant, 11, pp. 851-853; Takahashi, N., Shoji, T., Hirohata, M., Ishizu, T., Miki, S., Ono, S., Kaifu, Y., The effects of histamine H2-receptor antagonists on the phosphorus binding ability of calcium carbonate in hemodialysis patients (1999) J Jpn Soc Dial Ther, 28, pp. 1069-1074; Clough, M.R., Axon, A.T., The Calcium Carbonate Breath Test, a non invasive test of stimulated gastric acid secretion: preliminary communication (2009) Eur J Gastroenterol, 21, pp. 266-272; Goss, S., Lemons, K.A., Kerstetter, J.E., Bogner, R.H., Determination of calcium salt solubility with changes in pH and P (CO (2)), simulating varying gastrointestinal environments (2007) J Pharm Pharmacol, 59, pp. 1485-1492; Goss, S., Rafferty, P., Prushko, J., Gorman, E., Taub, M., Bogner, R., Exploration of intestinal calcium precipitation as a barrier to absorption at high calcium doses (2008) Pharmacol Res, 25, pp. 2760-2768; Slatopolsky, E., Brown, A., Dusso, A., Role of phosphorus in the pathogenesis of secondary hyperparathyroidism (2001) Am J Kidney Dis, 37 (2), pp. 54-57; Bricker, N.S., on the pathogenesis of the uremic state. An exposition of the trade-off hypothesis (2007) N Engl J Med, 286, pp. 1093-1099; Kinjo, M., Setoguchi, S., Solomon, D.H., Antihistamine therapy and bone mineral density: analysis in a population-based US sample (2008) Am J Med, 121, pp. 1085-1091; Roux, C., Briot, K., Gossec, L., Kolta, S., Blenk, T., Felsenber, D., Increase in vertebral fracture risk in postmenopausal women using omeprazole (2009) Calcif Tissue Int, 84, pp. 13-19; Hardy, P., Hottelart, C., Oprisiu, R., Abighanem, O., Oualim, Z., Rasombolona, M., Role of calcium carbonate administration timing in relation to food intake on its efficiency in controlling hyperphosphatemia in patients on maintenance hemodialysis (2002) Artif Organs, 22, pp. 564-568; Osler, P., Raniga, P., Farrington, K., Effect of omeprazole on the phosphate-binding capacity of calcium carbonate (1995) Nephron, 69, pp. 89-90. , (letter to the editor); Galetta, F., Cupisti, A., Franzoni, F., Femia, F.R., Rossi, M., Barsotti, G., Left ventricular function and calcium phosphate plasma levels in uremic patients (2005) J Intern Med, 258, pp. 378-384; Graziani, G., Badalamenti, S., Como, G., Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload (2002) Role of gastric acid secretion, Nephron, 91, pp. 474-479; Carr, C., Shangraw, R., Nutritional and pharmaceutical aspects of calcium supplementation (2005) Am Pharm, 27, pp. 49-50. , 54-57; Straub, D.A., Calcium supplementation in clinical practice: a review of forms, doses, and indications (2010) Nutr Clin Pract, 22, pp. 286-296; Yang, Y.X., Metz, D.C., Peptic ulcer disease, Diagnosis and Management (2002) Gastrointestinal Diseases: an Endoscopic Approach, pp. 385-410. , Al-Kawas F (ed.), 2 nd Edn, SLACK Incorporated, USA; Laine, L., Proton pump inhibitors and bone fractures (2009) Am J Gastro enterol, 104, pp. 21-26; Mizunashi, K., Furukawa, Y., Katano, K., Abe, K., Effect of omeprazole an inhibitor of H +/ K +-ATPase, on bone resorption in humans (2009) Calcif Tissue Int, 53, pp. 21-25; Hilliard, S.D., O'Donnell, J.F., Schenker, S., on the nature of the inhibitor of urinary alkaline phosphatase (1998) Clin Chem, 11, pp. 570-574; Fox, I.H., Uric acid (1998) Degradation of purine nucleotides, pp. 93-124. , Kelley WN and Weiner IM; Springer, Berlin
dcterms.sourceScopus

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description:
Download

Collections

Faculty Of Pharmacy Research Paper